Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 August;60(4) > Minerva Cardioangiologica 2012 August;60(4):363-73

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

  HEART FAILURE


Minerva Cardioangiologica 2012 August;60(4):363-73

language: English

Gene and cell therapies for the failing heart to prevent sudden arrhythmic death

Sovari A. A., Dudley S. C. Jr

Section of Cardiology and Center for Cardiovascular Research, University of Illinois at Chicago, Chicago, IL, USA


PDF  


Current therapies for treatment and prevention of sudden cardiac death have certain limitations, and a search for new therapeutic approaches is desirable to reduce the burden of sudden arrhythmic death. Gene therapy and stem cell therapy have been investigated as new, valuable tools in treating cardiac diseases such as arrhythmias. In this review, the basics of each modality, important related experimental and clinical studies, and potential advantages and limitations of these treatments will be discussed. The future success of gene and cell therapy to become practical clinical tools greatly depends on our understanding of the mechanisms of ventricular arrhythmia and the mechanisms of action of gene and cell therapy.

top of page

Publication History

Cite this article as

Corresponding author e-mail

scdudley@uic.edu